Posts

Pfizer advances Litfulo for vitiligo in face of Incyte and AbbVie competition

on

AbbVie scores dual EU approvals for Rinvoq in vitiligo, alopecia

on

AbbVie Scores First Rinvoq Alopecia Nod in EU

on

Sarepta Taps Former AbbVie and Tessera CEO Michael Severino as New CEO to Lead Duchenne Drugmaker's Turnaround

on

A rising tide scenario: Why other Big Pharmas could follow Lilly into psychedelics

on

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

on

AbbVie's $10.9B Move for Apogee's Long-Acting I&I Drug Candidates

on

Portal Biotechnologies raises $9M for cell engineering tech that’s attracted Merck & Co., AbbVie

on

AbbVie’s QULIPTA and Amgen’s Imdylltra Score New EU Approvals for Migraine and Lung Cancer Indications

on

AbbVie gains FDA nod for ultra‑rare blood cancer ADC from ImmunoGen deal

on

AbbVie’s Skyrizi yields to UCB’s Bimzelx in psoriatic arthritis head‑to‑head trial

on

AbbVie Reports Strong Skyrizi Sales Amid Wall Street Concerns Over J&J's Icotyde Pill

on

AbbVie Enters Competitive RAS Oncology Field with $1.45B Biobucks Deal for Kestrel Option

on

AbbVie's $1.4 Billion North Carolina Manufacturing Campus Announcement

on

AbbVie Inks $745M Deal with Haisco for Two Acute Pain Assets

on

AbbVie Sues Over 'Outdated' 340B Patient Definition in New Lawsuit

on

White House Adds AbbVie's Humira to TrumpRx at 86% Discount Alongside Biosimilars and Other Drugs

on

Recent Pharmaceutical Industry Developments: AbbVie's China Engagement and Biologics Expansion

on

AbbVie and Gubra Report Positive Phase 1 Obesity Data for ABBV-295

on

AbbVie Reports Up to 9.8% Weight Loss in Phase 1 Trial of Gubra-Partnered Amylin Analogue ABBV-295

on